Journal article
Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease
MA Roberts, E Velkoska, FL Ierino, LM Burrell
Nephrology Dialysis Transplantation | OXFORD UNIV PRESS | Published : 2013
DOI: 10.1093/ndt/gft038
Abstract
Background. Angiotensin-converting enzyme 2 (ACE2) is a novel regulator of the renin-angiotensin system that counteracts the adverse effects of angiotensin II. In heart failure patients, elevated plasma ACE2 activity predicted adverse events and greater myocardial dysfunction. We aimed to describe plasma ACE2 activity and its clinical associations in patients with kidney disease. Methods. Patients recruited from a single centre comprised of chronic kidney disease Stage III/IV (CKD), haemodialysis patients and kidney transplant recipients (KTRs). Plasma ACE2 enzyme activity was measured using a fluorescent substrate assay in plasma, collected at baseline and stored at -80°C. Linear regression..
View full abstractGrants
Awarded by Austin Medical Research Foundation
Funding Acknowledgements
Dr Roberts is supported by a National Health and Medical Research Council of Australia Health Professional Training Fellowship (628902). Dr Velkoska received support from the Austin Medical Research Foundation and the National Health and Medical Research Council (1048285) to enable the ACE2 assays to be performed.